IP Library Granted Patent US 7,393,631
Granted Patent B2
US 7,393,631 · App. 11/326,275 · Granted Jul 1, 2008

Method for purifying adenoviruses

Assignee: Schering Corporation
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,393,631
App. No.
11/326,275
Granted
Jul 1, 2008
Kind
B2
Abstract

Methods for purifying adenoviruses from a contaminated sample using a hydroxyapatite medium are provided. Sodium chloride concentrations present in buffers used throughout the method are at least 150 mM to prevent the adenovirus from irreversibly binding to the hydroxyapatite. Levels of contaminants and empty adenovirus capsids from samples purified by conventional purification techniques are further reduced to provide a highly pure adenovirus preparation.

Claims (19)

1. A method for purifying adenovirus from contaminants in a sample pool, comprising: contacting the sample pool with a hydroxyapatite chromatographic medium to reversibly bind the adenovirus to the hydroxyapatite; and eluting the bound adenovirus from the hydroxyapatite, wherein the sample pool comprises at least 150 mM concentration of sodium chloride and the elution buffer comprise at least 150 mM concentration of sodium chloride.

2. The method of claim 1 wherein the sample pool comprises sodium chloride in a concentration of from about 150 to 500 mM.

3. The method of claim 1 , wherein the hydroxyapatite chromatographic medium is equilibrated with a buffer comprising sodium chloride at a concentration of from about 150 to 500 mM before the step of contacting the sample pool with the hydroxyapatite.

4. The method of claim 1 , further comprising the step of washing the hydroxyapatite with a buffer comprising sodium chloride in a concentration of 150 to 500 mM, wherein the hydroxyapatite comprises an adenovirus bound thereto.

5. The method of claim 1 , wherein the adenovirus is eluted using a buffer comprising sodium chloride in a concentration from about 150 mM to 500 mM.

6. The method of claim 1 wherein the sodium chloride concentration in a buffer used in the method is from about 350 mM to 450 mM.

7. The method of claim 1 , wherein the sample pool is prepared from an eluate of a conventional chromatography medium.

8. The method of claim 7 wherein the conventional chromatography medium is: an anion exchange resin; an immobilized metal ion affinity resin; a size exclusion chromatography resin; or a medium used in hydrophobic interaction chromatography.

9. The method of claim 1 , wherein the eluting step is a gradient elution to 600 mM phosphate.

10. The method of claim 1 , wherein the eluting step is a step elution with 250 mM phosphate.

11. The method of claim 1 , wherein a buffer used in the method comprises glycerol or sucrose.

12. The method of claim 1 , wherein the concentration of adenovirus in the sample pool is equal to or less than 1.times.10.sup.14 particles per ml.

13. The method of claim 1 , wherein the adenovirus comprises a therapeutic gene.

14. The method of claim 1 , wherein the adenovirus is ACN53.

15. The method of claim 1 , wherein the adenovirus comprises a nucleic acid sequence from the p53 gene or from the p21 gene.

16. A method of claim 1 , which reduces the concentration of a contaminant in the sample pool by at least 80%.

17. A method of claim 1 , which reduces the concentration of empty capsids by at least 75%.

18. A method of claim 1 , which reduces the concentration of BSA by at least 70%.

19. A method for purifying adenovirus from contaminants in sample pool, comprising: contacting the sample pool with a hydroxyapatite chromatographic medium to reversibly bind the adenovirus to the hydroxyapatite; washing the adenovirus-bound hydroxyapatite with a buffered solution; and eluting the bound adenovirus from the hydroxyapatite, wherein the sample pool is a buffered solution comprising about 50 mM sodium phosphate pH about 7.5, about 400 mM sodium chloride, about 2% sucrose, about 2 mM MgCl.sub.2, and about 10% glycerol, and the concentration of total contaminants is reduced by at least 80%.

Assignments (1)
CHANGE OF NAME Recorded Aug 30, 2012
From: SCHERING CORPORATION
To: MERCK SHARP & DOHME CORP.
Reel/Frame 028884/0151 →
Continuity (3)
Continuation 0999108000 · Nov 16, 2001
Provisional Application 6025382300 · Nov 29, 2000
Related Publication 20060105456A1 · May 18, 2006